Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
SMTI
HOLDSanara MedTech Inc. · Healthcare · United States · $234M · Avg Vol: $2M/d
COMPANY DESCRIPTION
Sanara MedTech Inc. develops and commercializes advanced wound care and surgical tissue repair products, including biologics and sophisticated wound care solutions. The company offers a proprietary product portfolio rooted in regenerative medicine, supported by clinical evidence for efficacy and a specialized sales force. Sanara MedTech is a niche player in the growing wound care market, focusing on innovative solutions for complex medical cases.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 24.1M | 45.8M | 65.0M | 86.7M | 103.1M | 43.8% | 107.5M | 117.7M | 133.2M | 13.7% |
| EPS | -1.08 | -1.00 | -0.52 | -1.14 | -4.36 | — | — | — | — | — |
| Shares | 7.7M | 8.3M | 8.5M | 8.8M | 8.9M | +16.5% | 9.2M | — | — | — |
| Debt | 0.4M | 0.8M | 11.8M | 32.3M | 48.2M | 226.2% | 48.4M | — | — | — |
| Equity | 30.6M | 41.8M | 44.8M | 39.4M | 5.9M | -33.6% | — | — | — | — |
| Op CF | -4.8M | -5.6M | -3.2M | -23.8K | 6.8M | — | 6.3M | — | — | — |
| Inv CF | -5.3M | -3.5M | -10.2M | -6.6M | -15.0M | — | — | — | — | — |
| Fin CF | 28.3M | -0.6M | 9.6M | 17.4M | 8.9M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of SMTI are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| SMTI | Sanara MedTech Inc.(you) | $234M | 60 | HOLD |
| OSUR | OraSure Technologies, Inc. | $273M | 48 | HOLD |
| EMBC | Embecta Corp. | $195M | 74 | BUY |
| ANGO | AngioDynamics, Inc. | $562M | 58 | HOLD |
| PDEX | Pro-Dex, Inc. | $175M | 91 | STRONG BUY |
| STAA | STAAR Surgical Company | $1.2B | 55 | HOLD |
| KRMD | KORU Medical Systems, Inc. | $176M | 27 | SELL |
| UTMD | Utah Medical Products, Inc. | $214M | 97 | STRONG BUY |
| BLFS | BioLife Solutions, Inc. | $1.5B | 56 | HOLD |
| DXR | Daxor Corporation | $61M | 44 | HOLD |
Peer medians: ROE -25.6% · P/E 27.6x · Gross margin 50.5%